Target intelligence / Profile preview

Solute carrier family 9 member C1 (SLC9C1)

Target
SLC9C1
Molecular classification
Transporter, Ion transporter, Sodium-hydrogen exchanger (NHE) family
01

Overview

Solute carrier family 9 member C1 (SLC9C1), also known as NHE-10 or sNHE, is a transporter protein primarily expressed in sperm and testis, encoded by the SLC9C1 gene. SLC9C1 is a unique member of the sodium-hydrogen exchanger (NHE) family that functions as a voltage- and cyclic nucleotide-regulated Na+/H+ exchanger, promoting intracellular alkalinization by extruding protons in exchange for sodium ions. Unlike other NHEs, SLC9C1 contains both a voltage-sensing domain (VSD) and a cyclic-nucleotide binding domain (CNBD), facilitating rapid and regulated changes in intracellular pH critical for sperm motility and male fertility. SLC9C1 activation is essential for hyperactivation and fertilization, and mutations disrupting its function can cause male infertility. Additionally, SLC9C1 expression in osteoclasts suggests a role in bone metabolism, and experimental antibodies targeting SLC9C1 have been explored to inhibit bone resorption. Pathogenic mutations in SLC9C1 have been linked to reproductive disorders in humans, such as asthenozoospermia, and may also be associated with other diseases like Dent’s disease.

Other names
SLC9A10NHE-10Na(+)/H(+) exchanger 10Sodium/hydrogen exchanger 10Solute carrier family 9 member 10Sperm-specific Na(+)/H(+) exchangersNHEsperm-NHE
02

Mechanism of action

Inhibition of SLC9C1 function (e.g., by antibody) reduces bone resorption\nModulation of sodium/proton exchange by affecting voltage and cAMP gating

03

Biological functions

Regulation of intracellular pHSperm motilityMale fertilityVoltage and cAMP-regulated ion exchangeOsteoclast differentiation and survival
04

Disease associations

Male infertility (asthenozoospermia)Osteoclast-related bone diseasesPossible involvement in Dent’s disease (X-linked renal tubular disorder)
05

Safety considerations

Potential off-target effects on fertility and bone metabolism if targeted therapeutically
06

Interacting drugs

Anti-SLC9C1 monoclonal antibody (experimental, e.g., in targeted bone resorption therapy)
07

Biomarkers

SLC9C1 expression or mutations as potential biomarkers for male infertility (asthenozoospermia)

Beyond the preview

Go deeper on Solute carrier family 9 member C1 (SLC9C1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 9 member C1 (SLC9C1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call